First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.

about

Anti-angiogenesis target therapy for advanced osteosarcoma (Review).Metastatic and triple-negative breast cancer: challenges and treatment options

P2860

Q39401628-8CD700F0-2703-41E1-8CFD-79BC7CCF27C2 Q57105258-C0A38443-43F1-4AB6-BEB1-9E2059860A37

P2860

First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.

Item

http://www.wikidata.org/entity/Q50760615

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

First-line trastuzumab plus ta ...... r: cost-minimization analysis.

@en

First-line trastuzumab plus ta ...... r: cost-minimization analysis.

@nl

type

Item

label

First-line trastuzumab plus ta ...... r: cost-minimization analysis.

@en

First-line trastuzumab plus ta ...... r: cost-minimization analysis.

@nl

prefLabel

First-line trastuzumab plus ta ...... r: cost-minimization analysis.

@en

First-line trastuzumab plus ta ...... r: cost-minimization analysis.

@nl

P1476

First-line trastuzumab plus ta ...... er: cost-minimization analysis

@en

P2093

Aline Voidey

http://www.w3.org/2001/XMLSchema#string

Cristian Villanueva

http://www.w3.org/2001/XMLSchema#string

Frédéric Fiteni

http://www.w3.org/2001/XMLSchema#string

Jennifer Chelly

http://www.w3.org/2001/XMLSchema#string

Loïc Chaigneau

http://www.w3.org/2001/XMLSchema#string

Nathalie Meneveau

http://www.w3.org/2001/XMLSchema#string

Philippe Montcuquet

http://www.w3.org/2001/XMLSchema#string

Samuel Limat

http://www.w3.org/2001/XMLSchema#string

Sophie Perrin

http://www.w3.org/2001/XMLSchema#string

Tess Monnot

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Trastuzumab--mechanism of action and use in clinical practice

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality

Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.

Cost of cancer care: issues and implications.

P304

362-368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155213508440

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Xavier Pivot

P577

2013-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24158979

http://www.w3.org/2001/XMLSchema#string

First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.

about

P2860

P2860

First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698